Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
antioxidants · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| antioxidant tablets | EXPERIMENTAL | the study arm received antioxidant tablets (Icaps) for 3 months or until the resolution of the disease |
| placebo tablets | PLACEBO_COMPARATOR | the control arm received placebo tablets for 3 months or until the resolution of the disease |
| Name | Type | Description |
|---|---|---|
| antioxidants tablets | DRUG | vitamin A 6600 IU, vitamin C 400 mg, vitamin E 150 IU, riboflavin 10 mg, zinc 60 mg, copper 4 mg, selenium 40 mg, manganese 4 mg and lutein/zeaxanthin 4000 micrograms. |
Inclusion Criteria: 1. patients with acute central serous chorioretinopathy within 6 weeks of onset 2. age between 30-50 years 3. new or recurrent attack (the symptom-free period should longer than 6 months) 4. fluorescein angiography (FA) confirmed the diagnosis with the inkblot or smoke-stack lea...
Antioxidants are being studied as a treatment for Central Serous Chorioretinopathy, a condition that causes fluid buildup under the retina. The investigational therapy is being evaluated in a Phase 2 clinical trial to assess its effects on this eye disorder.
Alcon Inc. (NYSE: ALC) is developing antioxidants as an investigational treatment for Central Serous Chorioretinopathy. The company is conducting clinical research on this small molecule therapy to evaluate its potential in treating the condition.
Antioxidants are in Phase 2 clinical development for Central Serous Chorioretinopathy. The therapy is investigational and not yet approved, with one completed Phase 2 trial that enrolled 60 participants.
Antioxidants are being studied in the clinical trial NCT00963131, titled "High-dose Antioxidants for Central Serous Chorioretinopathy." This Phase 2, randomized, double-blind, placebo-controlled study was conducted in Thailand and enrolled 60 participants aged 30 years and older.
Yes, antioxidants are also referred to as high-dose antioxidants in clinical research. The Phase 2 trial NCT00963131 specifically evaluated high-dose antioxidants for Central Serous Chorioretinopathy, confirming this alternative name for the therapy.